BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

487 related articles for article (PubMed ID: 33329554)

  • 1. Impact of Long-Term Cryopreservation on Blood Immune Cell Markers in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome: Implications for Biomarker Discovery.
    Gómez-Mora E; Carrillo J; Urrea V; Rigau J; Alegre J; Cabrera C; Oltra E; Castro-Marrero J; Blanco J
    Front Immunol; 2020; 11():582330. PubMed ID: 33329554
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Association of T and NK Cell Phenotype With the Diagnosis of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS).
    Rivas JL; Palencia T; Fernández G; García M
    Front Immunol; 2018; 9():1028. PubMed ID: 29867995
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Novel identification and characterisation of Transient receptor potential melastatin 3 ion channels on Natural Killer cells and B lymphocytes: effects on cell signalling in Chronic fatigue syndrome/Myalgic encephalomyelitis patients.
    Nguyen T; Staines D; Nilius B; Smith P; Marshall-Gradisnik S
    Biol Res; 2016 May; 49(1):27. PubMed ID: 27245705
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunological abnormalities as potential biomarkers in Chronic Fatigue Syndrome/Myalgic Encephalomyelitis.
    Brenu EW; van Driel ML; Staines DR; Ashton KJ; Ramos SB; Keane J; Klimas NG; Marshall-Gradisnik SM
    J Transl Med; 2011 May; 9():81. PubMed ID: 21619669
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cellular Immune Function in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS).
    Cliff JM; King EC; Lee JS; Sepúlveda N; Wolf AS; Kingdon C; Bowman E; Dockrell HM; Nacul L; Lacerda E; Riley EM
    Front Immunol; 2019; 10():796. PubMed ID: 31057538
    [TBL] [Abstract][Full Text] [Related]  

  • 6. MicroRNAs hsa-miR-99b, hsa-miR-330, hsa-miR-126 and hsa-miR-30c: Potential Diagnostic Biomarkers in Natural Killer (NK) Cells of Patients with Chronic Fatigue Syndrome (CFS)/ Myalgic Encephalomyelitis (ME).
    Petty RD; McCarthy NE; Le Dieu R; Kerr JR
    PLoS One; 2016; 11(3):e0150904. PubMed ID: 26967895
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Characterisation of cell functions and receptors in Chronic Fatigue Syndrome/Myalgic Encephalomyelitis (CFS/ME).
    Hardcastle SL; Brenu EW; Johnston S; Nguyen T; Huth T; Wong N; Ramos S; Staines D; Marshall-Gradisnik S
    BMC Immunol; 2015 Jun; 16():35. PubMed ID: 26032326
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Validation of impaired Transient Receptor Potential Melastatin 3 ion channel activity in natural killer cells from Chronic Fatigue Syndrome/ Myalgic Encephalomyelitis patients.
    Cabanas H; Muraki K; Balinas C; Eaton-Fitch N; Staines D; Marshall-Gradisnik S
    Mol Med; 2019 Apr; 25(1):14. PubMed ID: 31014226
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pilot Study of Natural Killer Cells in Chronic Fatigue Syndrome/Myalgic Encephalomyelitis and Multiple Sclerosis.
    Huth TK; Brenu EW; Ramos S; Nguyen T; Broadley S; Staines D; Marshall-Gradisnik S
    Scand J Immunol; 2016 Jan; 83(1):44-51. PubMed ID: 26381393
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Longitudinal investigation of natural killer cells and cytokines in chronic fatigue syndrome/myalgic encephalomyelitis.
    Brenu EW; van Driel ML; Staines DR; Ashton KJ; Hardcastle SL; Keane J; Tajouri L; Peterson D; Ramos SB; Marshall-Gradisnik SM
    J Transl Med; 2012 May; 10():88. PubMed ID: 22571715
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rituximab impedes natural killer cell function in Chronic Fatigue Syndrome/Myalgic Encephalomyelitis patients: A pilot in vitro investigation.
    Eaton N; Cabanas H; Balinas C; Klein A; Staines D; Marshall-Gradisnik S
    BMC Pharmacol Toxicol; 2018 Mar; 19(1):12. PubMed ID: 29587879
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Novel characterisation of mast cell phenotypes from peripheral blood mononuclear cells in chronic fatigue syndrome/myalgic encephalomyelitis patients.
    Nguyen T; Johnston S; Chacko A; Gibson D; Cepon J; Smith P; Staines D; Marshall-Gradisnik S
    Asian Pac J Allergy Immunol; 2017 Jun; 35(2):75-81. PubMed ID: 27362406
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Longitudinal analysis of immune abnormalities in varying severities of Chronic Fatigue Syndrome/Myalgic Encephalomyelitis patients.
    Hardcastle SL; Brenu EW; Johnston S; Nguyen T; Huth T; Ramos S; Staines D; Marshall-Gradisnik S
    J Transl Med; 2015 Sep; 13():299. PubMed ID: 26370228
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Screening NK-, B- and T-cell phenotype and function in patients suffering from Chronic Fatigue Syndrome.
    Curriu M; Carrillo J; Massanella M; Rigau J; Alegre J; Puig J; Garcia-Quintana AM; Castro-Marrero J; Negredo E; Clotet B; Cabrera C; Blanco J
    J Transl Med; 2013 Mar; 11():68. PubMed ID: 23514202
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Transient receptor potential melastatin 2 channels are overexpressed in myalgic encephalomyelitis/chronic fatigue syndrome patients.
    Balinas C; Cabanas H; Staines D; Marshall-Gradisnik S
    J Transl Med; 2019 Dec; 17(1):401. PubMed ID: 31796045
    [TBL] [Abstract][Full Text] [Related]  

  • 16. ERK1/2, MEK1/2 and p38 downstream signalling molecules impaired in CD56 dim CD16+ and CD56 bright CD16 dim/- natural killer cells in Chronic Fatigue Syndrome/Myalgic Encephalomyelitis patients.
    Huth TK; Staines D; Marshall-Gradisnik S
    J Transl Med; 2016 Apr; 14():97. PubMed ID: 27098723
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Potential Therapeutic Benefit of Low Dose Naltrexone in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome: Role of Transient Receptor Potential Melastatin 3 Ion Channels in Pathophysiology and Treatment.
    Cabanas H; Muraki K; Eaton-Fitch N; Staines DR; Marshall-Gradisnik S
    Front Immunol; 2021; 12():687806. PubMed ID: 34326841
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Loss of Transient Receptor Potential Melastatin 3 ion channel function in natural killer cells from Chronic Fatigue Syndrome/Myalgic Encephalomyelitis patients.
    Cabanas H; Muraki K; Eaton N; Balinas C; Staines D; Marshall-Gradisnik S
    Mol Med; 2018 Aug; 24(1):44. PubMed ID: 30134818
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Role of adaptive and innate immune cells in chronic fatigue syndrome/myalgic encephalomyelitis.
    Brenu EW; Huth TK; Hardcastle SL; Fuller K; Kaur M; Johnston S; Ramos SB; Staines DR; Marshall-Gradisnik SM
    Int Immunol; 2014 Apr; 26(4):233-42. PubMed ID: 24343819
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Activin B is a novel biomarker for chronic fatigue syndrome/myalgic encephalomyelitis (CFS/ME) diagnosis: a cross sectional study.
    Lidbury BA; Kita B; Lewis DP; Hayward S; Ludlow H; Hedger MP; de Kretser DM
    J Transl Med; 2017 Mar; 15(1):60. PubMed ID: 28302133
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.